What is Pulmocide?
Pulmocide is a specialized biopharmaceutical company dedicated to developing novel treatments for common acute and chronic respiratory tract infections. These infections often lead to serious complications and significantly diminish patients' quality of life. By targeting the underlying causes of these debilitating conditions, Pulmocide aims to provide innovative therapeutic solutions that can improve patient outcomes and well-being. The company's focus on respiratory health positions it within a critical area of unmet medical need.
How much funding has Pulmocide raised?
Pulmocide has raised a total of $149.9M across 3 funding rounds:
Series A
$27.5M
Series B
$30.4M
Series C
$92M
Series A (2013): $27.5M with participation from F-Prime Capital Partners, Imperial Innovations Group plc, Johnson & Johnson Development Corporation, and S.V. Life Sciences
Series B (2017): $30.4M led by S.R. One, F-Prime Capital, Touchstone Innovations plc, JJDC, Inc, Longwood Fund, and S.V. Life Sciences
Series C (2021): $92M supported by Jeito Capital, Asahi Kasei Pharma, SV Health Investors, SR One, and Adjuvant Capital
Key Investors in Pulmocide
S.R. One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics. The firm partners with founders and scientific teams to translate innovative technologies and discoveries into new medicines.
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
What's next for Pulmocide?
With the recent infusion of capital from its Series C financing, Pulmocide is poised for accelerated development and expansion. This substantial backing, characterized as a major strategic investment, suggests a focus on scaling operations, advancing clinical trials, and potentially broadening its therapeutic pipeline. The company's trajectory indicates a move towards late-stage development and commercialization, leveraging its scientific advancements to tackle significant respiratory health challenges. Future endeavors will likely involve strategic partnerships and further R&D to solidify its market position in the biopharmaceutical sector.
See full Pulmocide company page
